Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
05 janv. 2022 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference 5 January 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a...
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases
12 déc. 2021 09h01 HE
|
Silence Therapeutics plc
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and...
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
01 déc. 2021 07h00 HE
|
Silence Therapeutics plc
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA)...
Silence Therapeutics Begins Exclusive Nasdaq Trading
30 nov. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and...
Silence Therapeutics to Present at Jefferies London Healthcare Conference
11 nov. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
05 nov. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
21 oct. 2021 08h30 HE
|
Silence Therapeutics plc
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication...
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
15 oct. 2021 07h05 HE
|
Silence Therapeutics plc
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be...
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform
15 oct. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform Hansoh will make a $16 million upfront cash payment and Silence has the...
Silence Therapeutics to Host R&D Day on October 21, 2021
07 oct. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...